The agency is reviewing data on secondary malignancies related to T-cells for approved CAR T-cell medicines.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
The European Medicines Agency (EMA) announced on Jan. 12, 2024 that its Pharmacovigilance Risk Assessment Committee (PRAC) was beginning a review of data on secondary malignancies related to T-cells for six approved chimeric antigen receptor (CAR) T-cell medicines. The committee is reviewing data from 23 cases of T-cell lymphoma or leukemia in the European Union’s EudraVigilance adverse event database.
According to EMA, secondary malignancies are those that develop when a cancer patient develops a second cancer that is different from the original cancer. This risk was considered at the time of authorization of the impacted drugs and included in risk management plans. The drugs have been monitored, and the marketing authorization holders are required to submit interim results from long-term and efficacy studies.
The impacted drugs—Breyanzi, Carvykti, Kymriah, Tecartus, and Yescarta—are approved in the EU and are used to treat blood cancers such as B-cell leukemia, B-cell lymphoma, follicular lymphoma, multiple myeloma, and mantle cell lymphoma in patients whose cancer has relapsed or has stopped responding to previous treatment. They are “personalized cancer immunotherapies where patients' white blood cells (T-cells) are reprogrammed and reinjected to attack the cancer.”
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.